3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
327
Neoplasm Metastasis
31
Advanced Breast Cancer
19
Neoplasms
17
Ovarian Neoplasms
11
Hereditary Sensory and Autonomic Neuropathies
10
Triple Negative Breast Neoplasms
8
Prostatic Neoplasms
7
Endometrial Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Breast Cancer Metastatic
6
Uterine Cervical Neoplasms
5
Breast Diseases
5
Squamous Cell Carcinoma of Head and Neck
4
Neoplasms by Site
4
Colorectal Neoplasms
4
Carcinoma, Ovarian Epithelial
4
Small Cell Lung Carcinoma
3
Recurrence
3
Multiple Endocrine Neoplasia Type 1
3
Head and Neck Neoplasms
3
Breast Neoplasm Female
3
Uterine Neoplasms
2
Stomach Neoplasms
2
Pancreatic Neoplasms
2
Locally Advanced (Inoperable) or Metastatic Breast Cancer
2
Liposarcoma
2
Hyperglycemia
2
HER2-positive Metastatic Breast Cancer
2
HER2-positive Breast Cancer
2
Interventions
pembrolizumab
3
spartalizumab
2
sargramostim
2
trametinib
1
tislelizumab
1
nazartinib
1
fludarabine phosphate
1
enzalutamide
1
canakinumab
1
bemarituzumab
1
Specimen Handling
1
Midazolam
1
Magnetic Resonance Spectroscopy
1
Letrozole
1
Interleukin-13
1
IFL protocol
1
Fulvestrant
1
Fluorodeoxyglucose F18
1
Cyclophosphamide
1
Cetuximab
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma of Lung
×
Fulvestrant
×
Breast
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled